4-Phenylbutyrate Rescue in GABRA1 Variants Associated with Developmental Epileptic Encephalopathies: from Cell and Mouse Models to Human

This study demonstrates that 4-phenylbutyrate (PBA) rescues GABAAR expression, trafficking, and function in both cellular and mouse models of GABRA1-associated developmental epileptic encephalopathies by enhancing proteostasis, suggesting its potential as a broad therapeutic strategy for genetic neurologic disorders sharing similar protein-folding pathologies.

The Gist

Imagine your brain is a bustling city where billions of tiny messengers (neurons) need to talk to each other to keep everything running smoothly. To stop the city from getting too chaotic or "overheated," there are special traffic lights called GABA receptors. These lights tell the messengers when to slow down and take a break.

In some people, a typo in their genetic blueprint (a mutation in the GABRA1 gene) causes these traffic lights to be built incorrectly. Because of this typo, the lights get stuck in the factory (the cell) and never make it out to the streets (the cell surface). Without enough working lights on the street, the brain's traffic gets out of control, leading to severe seizures and developmental delays. This condition is known as a Developmental Epileptic Encephalopathy (DEE).

The Problem with the Current Situation
Even though we know these traffic lights are the key to calming the brain, there hasn't been a good way to fix the broken ones caused by these specific genetic typos.

The Proposed Solution: 4-Phenylbutyrate (PBA)
The researchers in this paper tested a drug called 4-phenylbutyrate (PBA). You can think of PBA as a "factory foreman" or a "quality control manager" that steps in to help the construction crew.

Here is what the study found, step-by-step:

1. The Factory Glitch: Using computer models and lab tests, they confirmed that the mutated GABRA1 proteins are unstable. They are like wobbly Lego structures that the cell's quality control system detects as defective and throws away before they can be used. This means there are fewer traffic lights on the brain's surface.
2. The Drug's Effect in the Lab: When they added PBA to cells in a dish, it acted like a stabilizing glue. It helped the wobbly, mutated proteins hold their shape. As a result:
   • More of the broken proteins survived the factory process.
   • More of them successfully traveled to the cell surface.
   • Even when the cells had a mix of good and bad proteins, PBA helped both types get to the surface.
   • The traffic lights that did arrive actually worked better, allowing more "calm down" signals to pass through.
3. The Drug's Effect in Mice: They tested this on mice that had the same genetic mutation as the humans in the study. When they gave the mice PBA, they found that the drug successfully increased the number of working traffic lights in the thalamus (a deep part of the brain involved in these seizures).

The Big Picture
The study concludes that PBA is a promising tool for fixing this specific type of brain traffic jam. The drug works by helping the cell's internal factory manage its "proteostasis" (protein balance). It doesn't just fix the broken parts; it also helps the healthy parts work better and reduces the stress on the factory itself.

Based on this work and their previous studies on similar genetic errors, the authors suggest that PBA could be a "common medicine" for a group of different neurological disorders that share this same problem of unstable proteins. It offers hope that one drug might be able to help many different people with different genetic typos, as long as those typos cause the same kind of factory stress.

Technical Summary

Technical Summary: 4-Phenylbutyrate Rescue in GABRA1 Variants

Problem Statement
Developmental and epileptic encephalopathies (DEEs) are frequently caused by disease variants in GABR genes, which encode subunits of the $\gamma$-Aminobutyric acid type A receptor (GABAAR). Despite GABAAR being a primary target for antiseizure medications, there is currently no effective treatment for these specific genetic DEEs. While the authors previously identified a therapeutic effect of 4-phenylbutyrate (PBA) in Gabrg2 knockin mice, the efficacy of PBA in variants encoding the $\alpha1$ subunit (GABRA1) remained untested.

Methodology
The study employed a multidisciplinary approach to evaluate the impact of PBA on GABRA1 variants, specifically the A322D mutation. The experimental design integrated:

• In Silico Modeling: Structural modeling to predict protein stability, utilizing $\Delta\Delta G$ values to assess the thermodynamic impact of variants.
• In Vitro Models: Heterologous HEK293T cell systems were used to express wild-type and mutant alleles. Techniques included differential tagging of alleles, flow cytometry, biochemistry, and patch clamp recordings to measure GABA-evoked current amplitudes.
• In Vivo Models: Gabra1^+/A322D knockin mice were utilized to assess drug effects in a physiological context, specifically examining protein expression in the thalamus.

Key Results

1. Pathophysiology of Variants: The presence of the variant $\alpha1$ protein resulted in reduced total and cell surface expression of the subunit, suggesting a deficit in functional receptors at the cell membrane and synapse. Patch clamp recordings confirmed that GABRA1 variants significantly reduced GABA-evoked current amplitudes.
2. Mechanism of Defect: In silico predictions indicated that the variants possess reduced protein stability, evidenced by negative $\Delta\Delta G$ values.
3. Therapeutic Effect of PBA:
   • In Vitro: PBA treatment increased both total and surface expression of wild-type $\alpha1$ and the variant $\alpha1$ proteins. Crucially, PBA improved the expression of both wild-type and variant alleles when they were co-expressed.
   • In Vivo: PBA treatment successfully increased GABAAR expression in the thalamus of Gabra1^+/A322D mice.
4. Mechanism of Action: Consistent with previous findings on GABRG2 and SLC6A1 mutations, the study indicates that PBA mitigates proteostasis pathology by enhancing wild-type allele expression, repairing the mutant allele, and reducing endoplasmic reticulum (ER) stress.

Significance and Claims
The authors conclude that PBA represents a promising treatment option for DEEs associated with GABRA1 mutations. By restoring proteostasis, PBA is posited to mitigate seizures and improve neurobehavioral phenotypes. The study proposes that PBA holds potential as a common therapeutic agent for multiple genetic neurologic disorders that share a proteostasis pathology, suggesting a broad clinical application across various DEEs.